Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cordycepin Plus Pentostatin in Refractory TdT-Positive Leukemia
NCT00709215Phase 2Unknown
- Sponsor
- OncoVista Innovative Therapies
- Start
- Jun 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cordycepin in leukemia, sponsored by OncoVista Innovative Therapies. Primary endpoint: Recommended Dose (RD) of Cordycepin at 1 year. Status: unknown.
02
Drugs
cordycepin
03
Conditions
leukemia
Beyond the preview
Go deeper on NCT00709215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00709215.